Amgen receives EC approval for Repathaź (Evolocumab) to prevent heart attack and stroke
Amgen announced the EC has approved a new indication in the Repathaź (evolocumab) label for adults with established atherosclerotic cardiovascular disease (myocardial infarction, stroke or peripheral to reduce cardiovascular risk by lowering low-density LDL-C levels. May 16, 2018